ClinicalTrials.gg
Not yet recruitingNCT07462455Updated Sep 14, 2026

Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic(PK/PD) Profile of ACT500 in Metabolic Dysfunction-Associated Steatotic Liver Disease(MASLD)

A Phase 1 interventional study of ACT500 tablets in Metabolic Dysfunction-associated Steatohepatitis, sponsored by Xiamen Amoytop Biotech Co., Ltd.. Not yet recruiting at 4 sites in China. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by Xiamen Amoytop Biotech Co., Ltd. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 63 studies in Fatty Liver with a site in China — 30 open to participants now, 34 under way, 2 of them phase 3. Fatty Liver · China.

Planned enrollment
35th of 37
24 · median 90
Started
2026
with 10 others
Phase 1
6 of 63
3 open now
Primary completion
2027-02
later than 15 of 33 live
Registered
55th of 63
by date

Among the 63 studies in Fatty Liver with a site in China, this one is the 35th largest by planned enrollment of the 37 interventional ones that give a count, is one of 11 that started in 2026, is one of 6 in phase 1, reaches primary completion later than 15 of the 33 other live ones, and was the 55th registered.

Fatty Liver

663 studies on the registry are indexed under Fatty Liver; 185 are open to participants now.

Browse Fatty Liver studies →

Open to participants now

30 of the 63 studies in Fatty Liver with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 117 Fatty Liver studies recruiting now, 35 (30%) set no upper age limit and 63 (54%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 69 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Fatty Liver with a site in China, or all of them as a file.
02

Study summary

This study is a multicenter, open-label, dose-escalation trial designed to evaluate the safety, tolerability, PK, and PD profiles of ACT500 in participants with metabolic dysfunction-associated steatotic liver disease (MASLD). The trial plans to enroll approximately 24 MASLD participants across four dose cohorts, each consisting of 6 participants who will receive oral ACT500 once daily.

03

Conditions studied

  • Metabolic Dysfunction-associated Steatohepatitis

Browse trials for

Keywords

  • Metabolic Dysfunction-associated Steatohepatitis
  • ACT500
  • NM6606
04

Who can participate

Ages eligible
18 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant fully understands the purpose, nature, methods, and possible adverse reactions of the study, voluntarily participates in this study, and has signed the form.
  • Male or female participants aged between 18 and 69 years (inclusive of 18 and 69 years) at the time of signing the informed consent form.
  • Liver fat content (LFC) ≥10% as assessed by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) during the screening period.
  • Liver stiffness measurement (LSM) assessed by FibroScan during the screening period meets the criteria of 8 kPa ≤ LSM ≤ 15 kPa, OR a liver pathological result of F2/F3 fibrosis within 6 months prior to screening.
  • Serum (ALT) \<5× at screening.
  • Presence of at least one of the following metabolic risk factors:

    1. ≥ 24.0 kg/m\^2, or waist circumference ≥ 90 cm (males) and ≥ 85 cm (females);
    2. Presence of prediabetes: fasting blood glucose ≥ 6.1 mmol/L, or (HbA1c) ≥ 5.7%;
    3. History of type 2 diabetes mellitus;
    4. Fasting serum triglycerides (TG) ≥ 1.70 mmol/L but \< 5.6 mmol/L;
    5. Fasting serum high-density lipoprotein cholesterol ≤ 1.0 mmol/L (males) or ≤ 1.3 mmol/L (females), or on stable-dose lipid-lowering medication (excluding statins);
    6. Systolic blood pressure (SBP) ≥ 130 mmHg or diastolic blood pressure (DBP) ≥ 85 mmHg, while simultaneously meeting SBP ≤ 160 mmHg and DBP ≤ 100 mmHg, OR currently receiving a stable dose of antihypertensive medication and meeting SBP ≤ 160 mmHg and DBP ≤ 100 mmHg.
  • Both male and female participants must agree to use appropriate methods, as follows:

    1. For male participants: Agreement to use reliable contraceptive measures and refrain from sperm donation from signing the informed consent form until 1 months after the last dose.
    2. For female participants: Female participants of non-; OR female participants of childbearing potential who are not pregnant or breastfeeding, have a negative serum pregnancy test at screening and within 1 day prior to the first dose, and agree to use reliable contraceptive measures and refrain from egg donation from signing the informed consent form until 1 months after the last dose.

Exclusion criteria

Exclusion Criteria:

  • [1] Combined with other liver diseases, including but not limited to , , drug-induced liver disease, alcoholic liver disease, liver disease, suspected or confirmed hepatocellular carcinoma, etc.

    [2] Have a history of or currently have other , liver cirrhosis (including confirmed or suspected liver cirrhosis by imaging examination, or liver cirrhosis confirmed by liver ), or have evidence of decompensated liver disease (such as ascites, esophageal and gastric variceal bleeding, or hepatic encephalopathy, etc.), or have a history of liver transplantation.

    [3] Have a history of or current symptoms of severe cardiovascular and cerebrovascular diseases, including but not limited to uncontrolled or severe arrhythmias (ventricular fibrillation, atrial fibrillation, etc.), myocardial infarction, coronary heart disease, etc.

    [4] Have a history of persistent, respiratory, neurological, gastrointestinal, immunological, hematological, or psychiatric diseases, which, in the investigator's judgment, would pose additional risk to the participant.

    [5] Type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus (fasting plasma glucose >9 mmol/L within 3 months prior to screening, or >9.5% at screening); or patients with diabetes receiving anti-hyperglycemic medications other than metformin and insulin.

    [6] Have an estimated (eGFR) \<60 mL/min/1.73 m² at screening or a history of severe renal impairment.

    [7] Have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia; or have \<105 g/L for female participants or \<115 g/L for male participants at screening; or any other condition known to interfere with hemoglobin measurement as judged by the investigator.

    [8] Any of the following laboratory abnormalities at screening: alkaline phosphatase (ALP) >2× (ULN); total serum (TBIL) >1.5×ULN (excluding participants with benign unconjugated hyperbilirubinemia deemed eligible for enrollment by the Investigator, with total bilirubin \<2×ULN and direct bilirubin \<ULN); (INR) >1.3.

    [9] Have had a body weight change (increase or decrease) of >5% within 3 months prior to screening, or have undergone dieting, bariatric surgery, or used medications approved for weight loss indications.

    [10] Have a history of major trauma or surgery within 3 months prior to screening, or plan to undergo surgery during the study period.

    [11] Have a history of excessive alcohol consumption for 3 consecutive months or more within 1 year prior to screening, defined as a weekly ethanol intake of ≥210 g for males and ≥140 g for females; or have a history of drug abuse/dependence or a history of illicit drug inhalation/injection within 1 year prior to screening.

    [12] Have used medications that may have a therapeutic effect on MASLD/MASH (e.g., GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors, FGF21 analogs, resmetirom, etc.) or medications that may cause MASLD/MASH (e.g., amiodarone, methotrexate, tetracyclines, tamoxifen, estrogens at doses greater than hormone replacement therapy, anabolic steroids, valproic acid, other known hepatotoxic drugs, etc.) within 3 months prior to screening, or other medications that the investigator considers may affect the trial.

    [13] Have participated in another drug clinical trial within 3 months prior to screening.

    [14]Positive antibody (HIV-Ab) at screening; or positive treponema pallidum antibody together with positive rapid plasma reagin (RPR) test (RPR shall only be performed when treponema pallidum antibody is positive).

    [15] Have a known allergy to the of ACT500 or to drugs with a similar chemical structure to ACT500, or have other drug allergies that, in the investigator's judgment, preclude participation in the study.

    [16] Have any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in this study, or are unable to participate in the trial due to the participant's own reasons after signing the form (ICF).

Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    60 mg ACT500 tablet group

    Drug: ACT500 tablets

  • Experimental
    160 mg ACT500 tablet group

    Drug: ACT500 tablets

  • Experimental
    300 mg ACT500 tablet group

    Drug: ACT500 tablets

  • Experimental
    400 mg ACT500 tablet group

    Drug: ACT500 tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse Event#AE#

    Time frame: Day1-112

  2. Serious Adverse Event

    Time frame: Day1-112

  3. body temperature

    Time frame: Day 1,14,29,56,84,112

  4. Number of participants with treatment-related adverse events as assessed by NCI-CTCAE v6.0

    Time frame: Day 1,14,29,56,84,112

  5. pulse

    Time frame: Day 1,14,29,56,84,112

  6. heart rate

    Time frame: Day 1,14,29,56,84,112

  7. blood pressure

    Time frame: Day 1,14,29,56,84,112

  8. Number of Participants with Abnormal Laboratory Parameters Findings

    Time frame: Day 1,14,29,56,84,112

  9. Number of participants with clinically significant change from baseline in physical examination

    Time frame: Day 1,14,29,56,84,112

  10. Heart Rate

    Time frame: Day 14,29,56,84,112,

  11. PR Interval

    Time frame: Day 14,29,56,84,112,

  12. QRS Interval

    Time frame: Day 14,29,56,84,112,

  13. QT Interval

    Time frame: Day 14,29,56,84,112,

  14. QTc Interval

    Time frame: Day 14,29,56,84,112,

Secondary outcomes

  1. Area Under Curve(0-t)

    Time frame: Day 1,2,14,28,29

  2. Area Under the Concentration-time curve from time zero to τ at steady state

    Time frame: Day 1,2,14,28,29

  3. Area Under Curve(0-∞)

    Time frame: Day 1,2,14,28,29

  4. Maximum Plasma Concentration

    Time frame: Day 1,2,14,28,29

  5. Time to Maximum (plasma) Concentration

    Time frame: Day 1,2,14,28,29

  6. Elimination Half-Life

    Time frame: Day 1,2,14,28,29

  7. CL/F

    Time frame: Day 1,2,14,28,29

  8. Apparent Volume of Distribution

    Time frame: Day 1,2,14,28,29

  9. Cmin,ss

    Time frame: Day 1,2,14,28,29

  10. Cav,ss

    Time frame: Day 1,2,14,28,29

  11. Rac_Cmax

    Time frame: Day 1,2,14,28,29

  12. Rac_AUC0-tau

    Time frame: Day 1,2,14,28,29

  13. DF

    Time frame: Day 1,2,14,28,29

  14. MRI-PDFF-determined liver fat content (LFC)

    Time frame: Day 29,112

  15. Fibroscan-measured liver stiffness measurement (LSM)

    Time frame: Day 29,112

  16. AST/PLT Ratio Index,APRI

    Time frame: Day 1,14,29,56,84,112

  17. absolute change from baseline in ELF

    Time frame: Day 1,14,29,56,84,112

  18. percent change from baseline in ELF

    Time frame: Day 1,14,29,56,84,112

  19. Total Cholesterol

    Time frame: Day 1,14,29,56,84,112

  20. Triglyceride

    Time frame: Day 1,14,29,56,84,112

  21. Low-Density Lipoprotein Cholesterol

    Time frame: Day 1,14,29,56,84,112

  22. High-Density Lipoprotein Cholesterol

    Time frame: Day 1,14,29,56,84,112

  23. apolipoprotein A1

    Time frame: Day 1,14,29,56,84,112

  24. apolipoprotein B

    Time frame: Day 1,14,29,56,84,112

  25. absolute change from baseline in lipoprotein(a)

    Time frame: Day 1,14,29,56,84,112

  26. percent change from baseline in lipoprotein(a)

    Time frame: Day 1,14,29,56,84,112

  27. Alanine Aminotransferase

    Time frame: Day 1,14,29,56,84,112

  28. Aspartate Aminotransferase

    Time frame: Day 1,14,29,56,84,112

  29. Gamma-Glutamyl Transferase(GGT)

    Time frame: Day 1,14,29,56,84,112

  30. absolute change from baseline in GGT

    Time frame: Day 1,14,29,56,84,112

  31. percent change from baseline in GGT

    Time frame: Day 1,14,29,56,84,112

  32. body weight

    Time frame: Day 1,14,29,56,84,112

  33. body Mass Index

    Time frame: Day 1,14,29,56,84,112

  34. waist circumference

    Time frame: Day 1,14,29,56,84,112

  35. absolute change from baseline in hip circumference

    Time frame: Day 1,14,29,56,84,112

  36. High-sensitivity C-reactive protein

    Time frame: Day 1,2,14,28,29

  37. Tumor Necrosis Factor alpha

    Time frame: Day 1,2,14,28,29

  38. Cytokeratin 18 (M30)

    Time frame: Day 1,2,14,28,29

  39. N-terminal propeptide of type III collagen (Pro-C3)

    Time frame: Day 1,14,29

  40. absolute change from baseline in Pro-C3

    Time frame: Day 1,1429

  41. percent change from baseline in Pro-C3

    Time frame: Day 1,14,29

  42. Insulin-like Growth Factors-1

    Time frame: Day 1,14,29

  43. Insulin-like Growth Factor Binding Protein 3 (IGFBP-3)

    Time frame: Day 1,29

  44. absolute change from baseline in IGFBP-3

    Time frame: Day 1,29

  45. percent change from baseline in IGFBP-3

    Time frame: Day 1,29

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Feb 2027, 3 months later.

Of 22 phase 1 interventional studies under Fatty Liver, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2026
First posted
Mar 10, 2026
StartEst.
Oct 31, 2026
Primary completionEst.
Feb 28, 2027
CompletionEst.
Apr 30, 2027
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07462455
Collaborators
Beijing Tsinghua Changgeng Hospital
Responsible party
Sponsor
First posted
Mar 10, 2026
Start date
Oct 31, 2026 (estimated)
Primary completion
Feb 28, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Sep 14, 2026

Study contacts

Lai Wei
Contact
weelai@163.com
01056118930
Lai Wei
principal investigator · Beijing Tsinghua Changgeng Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ACT500

Start the discussion